Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection

Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus

(2014) Ana M. Chamoun-Emanuelli et al.   ANTIVIRAL RESEARCH

Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity

(2014) Siwaporn Boonyasuppayakorn et al.   ANTIVIRAL RESEARCH

Anti-Dengue-Virus Activity and Structure-Activity Relationship Studies of Lycorine Derivatives

(2014) Peng Wang et al.   ChemMedChem

Repurposing of Prochlorperazine for Use Against Dengue Virus Infection

(2014) Yogy Simanjuntak et al.   JOURNAL OF INFECTIOUS DISEASES

Determining the Involvement and Therapeutic Implications of Host Cellular Factors in Hepatitis C Virus Cell-to-Cell Spread

(2014) N. Barretto et al.   JOURNAL OF VIROLOGY

Hepatitis C drugs not reaching poor

(2014) Ewen Callaway   NATURE

Hepatitis C Virus Testing of Persons Born During 1945–1965: Recommendations From the Centers for Disease Control and Prevention

(2013) Bryce D. Smith et al.   ANNALS OF INTERNAL MEDICINE

Phenothiazines Inhibit Hepatitis C Virus Entry, Likely by Increasing the Fluidity of Cholesterol-Rich Membranes

(2013) Ana M. Chamoun-Emanuelli et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel Cell-Based Hepatitis C Virus Infection Assay for Quantitative High-Throughput Screening of Anti-Hepatitis C Virus Compounds

(2013) Zongyi Hu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The antimalarial ferroquine is an inhibitor of hepatitis C virus

(2013) Thibaut Vausselin et al.   HEPATOLOGY

Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly

(2013) Qisheng Li et al.   NATURE MEDICINE

Global control of hepatitis C: where challenge meets opportunity

(2013) David L Thomas   NATURE MEDICINE

Current progress in development of hepatitis C virus vaccines

(2013) T Jake Liang   NATURE MEDICINE

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies

(2013) Troels K H Scheel et al.   NATURE MEDICINE

Current and Future Therapies for Hepatitis C Virus Infection

(2013) T. Jake Liang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

(2013) J. Guedj et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression of heterologous proteins flanked by NS3-4A cleavage sites within the hepatitis C virus polyprotein

(2013) Joshua A. Horwitz et al.   VIROLOGY

Identification of Hepatitis C Virus Inhibitors Targeting Different Aspects of Infection Using a Cell-Based Assay

(2012) Xuemei Yu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding

(2012) Shufeng Liu et al.   HEPATOLOGY

Identification of the Niemann-Pick C1–like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor

(2012) Bruno Sainz et al.   NATURE MEDICINE

Histamine and H1-antihistamines: Celebrating a century of progress

(2011) F. Estelle R. Simons et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy

(2011) Joachim Lupberger et al.   NATURE MEDICINE

Mining for therapeutic gold

(2011) Francis S. Collins   NATURE REVIEWS DRUG DISCOVERY

The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics

(2011) R. Huang et al.   Science Translational Medicine

ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo

(2010) Hiromi Abe et al.   JOURNAL OF HEPATOLOGY

Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus

(2010) Michael J. Sofia et al.   JOURNAL OF MEDICINAL CHEMISTRY

Exploiting Drug Repositioning for Discovery of a Novel HIV Combination Therapy

(2010) C. L. Clouser et al.   JOURNAL OF VIROLOGY

Production of Infectious Hepatitis C Virus by Using RNA Polymerase I-Mediated Transcription

(2010) T. Masaki et al.   JOURNAL OF VIROLOGY

A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle

(2010) Karuppiah Chockalingam et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection

(2009) P. Gastaminza et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs

(2008) Judith M. Gottwein et al.   HEPATOLOGY

Mouse models for the study of HCV infection and virus–host interactions

(2008) Heidi Barth et al.   JOURNAL OF HEPATOLOGY

Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis

(2008) Shirit Einav et al.   NATURE BIOTECHNOLOGY